Mechanism study of miR-324-3p driving myocardial infarction progression through regulation of myocardial inflammation Authors: Hongxia Liu, Wenjing Zhu, Wenzheng Wang, Ruishuang Tang Published: 2026 ABSTRACT AbstractObjectivesThis study aims to analyze the expression of miR-324-3p in acute myocardial infarction (AMI), as well as its regulatory effects on inflammatory responses, oxidative stress, and cell viability in cardiomyocytes.MethodThis study enrolled 77 AMI patients and 82 healthy controls. The serum miR-324-3p levels were detected using qRT-PCR, and their diagnostic efficacy was evaluated through ROC analysis. Then construct the H/R injury model to analyze the damage of inflammatory factors, oxidative stress, and cell viability to H9c2 cardiomyocytes. Through the combination of site prediction, luciferase reporter gene validation, and STAT3 gene rescue experiments, the critical role of STAT3 in the regulation of miR-324-3p was revealed.ResultsIn AMI patients, miR-324-3p is significantly upregulated and has high diagnostic value. Overexpression of miR-324-3p exacerbates H/R-induced inflammation, while its inhibition alleviates inflammation. Under H/R treatment, the expression of miR-324-3p increased while the expression of STAT3 decreased. Knocking down STAT3 can reverse the protective effect of the miR-324-3p inhibitor, further confirming the critical role of STAT3 in the miR-324-3p regulatory pathway.ConclusionsThe abnormal elevation of miR-324-3p has a potential diagnostic value for AMI. miR-324-3p plays a significant role in H/R-injured cardiomyocytes by targeting and inhibiting the expression of STAT3.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s13019-026-04497-9.Keywords: Acute myocardial Infarction, miR-324-3p, STAT3, Inflammation Introduction Acute myocardial infarction (AMI) represents myocardial necrosis resulting from acute and sustained ischemic and hypoxic conditions of the coronary arteries [1]. The pathogenesis of AMI is intricate, pertaining to numerous facets such as myocardial cell injury, inflammatory response, oxidative stress, and cell apoptosis [2, 3]. Even though modern medicine has made certain breakthroughs in the diagnosis and treatment of AMI, the complex pathogenic mechanisms behind it remain not fully deciphered. Currently, numerous factors such as inflammatory responses, cell apoptosis, and oxidative stress play pivotal roles in the occurrence and progression of AMI. Once AMI is triggered, the necrosis of myocardial cells will provoke a local immune response [4], attracting a large number of inflammatory cells to aggregate and infiltrate, and releasing inflammatory mediators [5]. These inflammatory mediators will further exacerbate the damage to myocardial cells and promote their death, subsequently triggering myocardial remodeling and a decline in cardiac function, further worsening the survival state of myocardial cells. Furthermore, the substantial production of ROS during H/R in the myocardium leads to oxidative stress, which disrupts cellular structure and function [6]. Therefore, in-depth research into the mechanisms by which miR-324-3p regulates myocardial inflammation to drive the progression of AMI is of great significance for elucidating the pathological processes of AMI, discovering new potential therapeutic targets, and improving clinical intervention strategies. In recent years, the impact of non-coding RNAs, particularly miRNAs, in AMI has garnered widespread attention [7]. miRNAs play crucial regulatory roles in various physiological and pathological processes [8, 9]. Studies have found that miR-324-3p abnormal expression in the pathological process of vascular calcification and hypoxia-induced cardiomyocyte injury, suggesting its potential involvement in the pathological regulation of myocardial ischemic injury [10–12]. Moreover, numerous studies indicate that miR-324-3p exerts a crucial influence on regulating oxidative stress and inflammatory reactions [13, 14]. Studies utilizing the detection of cytokine expression have demonstrated that miR-324-3p is likely a key factor involved in the regulation of inflammatory responses [14]. However, the specific molecular mechanisms and regulatory networks of this miRNA in the occurrence and development of AMI remain unclear. Therefore, this study selected miR-324-3p as the core research subject, aiming to uncover its role and pathway in AMI. The abnormal activation of STAT3 is closely linked to myocardial inflammatory responses, cellular apoptosis, and oxidative stress [15]. It can influence the expression of multiple downstream inflammatory factors, thereby exacerbating myocardial injury [16]. Studies have reported that miRNA can regulate the function of STAT3 by targeting it, which provides a theoretical basis for the role of miR-324-3p in AMI through the regulation of STAT3. Based on the analysis of literature [17–20], it has been found that STAT3 plays a crucial role not only in the inflammatory response but also in the pathological processes such as apoptosis in MI [21]. Previous studies have confirmed that it can be translationally repressed by miRNAs through binding to the 3’-UTR region, but STAT3 as a target of miR-324-3p has not yet been reported. Based on this, the present study selected STAT3 as the downstream target gene of miR-324-3p for in-depth investigation. It is anticipated that a systematic analysis of miR-324-3p target genes in the future will provide a better explanation in the treatment of AMI. Based on the above background, this study focuses on the diagnostic value of miR-324-3p in AMI patients. Subsequently, cell experiments based on clinical findings were conducted to further clarify the regulatory role and mechanism of miR-324-3p in AMI-induced cellular injury. This study aims to provide new molecular targets and a theoretical foundation for the prevention and treatment of AMI. Materials and methods Study population Tangshan Third Hospital selected 77 AMI patients as the case group, and the diagnosis of AMI needed to meet the following criteria [22]: (1) Presence of typical chest pain symptoms; (2) Elevation and/or decrease in myocardial injury markers; (3) Electrocardiogram changes (ST elevation or depression; wide and deep Q waves; T wave inversion), etc. Exclusion criteria: (1) Severe hepatic and renal insufficiency, immune system diseases, etc.; (2) The patient is currently taking medications that may affect marker levels, such as statins, ACE inhibitors, anti-inflammatory drugs, etc.; (3) The patient has AMI-related complications or other cardiovascular diseases that may interfere with the study results. All AMI patients were admitted to the hospital within 6 h of onset. Additionally, 82 healthy controls were included. This work has been approved by the Ethics Committee of Tangshan Third Hospital. Quantitative real-time PCR analysis After collecting serum samples from AMI patients and healthy controls, followed by the extraction of total RNA via the Trizol method (Invitrogen, Carlsbad, CA, USA). The qPCR reaction was performed using miR-324-3p specific primers and the SYBR Premix Ex Taq kit (Takara, Japan), with the internal reference gene (U6 small nuclear RNA) primers set to calibrate the expression level of miR-324-3p. The primer sequences are provided in Supplementary Table 1. The relative expression level of miR-324-3p was determined using the 2−ΔΔCT. The detection of miR-324-3p in H9c2 cells also follows the above steps. Cell culture and cell transfection H/R treatment was used on rat cardiomyocyte progenitor cells H9c2 to construct an in vitro model of myocardial ischemia-reperfusion injury, and the level of miR-324-3p in cells was regulated by transfecting miR-324-3p mimics or inhibitors. The miR-324-3p mimics, inhibitor, their negative controls, si-STAT3, and negative control siRNA were all purchased from RiboBio (Guangzhou, China). According to previous studies in H9c2 cells, the miR-324-3p inhibitor and si-STAT3 were both used at a concentration of 50 nM [23, 24]. Transfection was carried out using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instructions. The transfection efficiency of the miR-324-3p mimic and inhibitor was verified by qRT-PCR without H/R treatment. The knockdown efficiency of si-STAT3 was also confirmed by qRT-PCR. The following groups were established: H/R model, H/R + miR-324-3p mimics, H/R + miR-324-3p inhibitors, and the corresponding negative control (NC) groups. Hypoxia/reoxygenation Before subjecting H9c2 cells to different treatments, H9c2 cells reached 80% confluence, the medium was replaced with serum- and glucose-free DMEM. Subsequently, the cells were placed in a hypoxic incubator, and the normal air was replaced with 95% nitrogen (N₂) and 5% carbon dioxide (CO₂). Cells were cultured under hypoxia for 15 h, then transferred to a normoxic incubator with fresh medium for an extra hour, and all experiments were triplicated. These hypoxia/reoxygenation conditions were optimized based on preliminary experiments in our laboratory and were consistent with previously published studies using H9c2 cells [25]. Enzyme-linked immunosorbent assay (ELISA) The supernatant levels of TNF-α, IL-6, and IL-1β were assessed with an ELISA kit (R&D Systems, Minneapolis, MN, USA) following the product manual, with results in pg/ml [26, 27]. Oxidative stress indicator testing The intracellular oxidative stress indicators, MDA content and SOD activity, were measured using commercial kits (Beyotime, Shanghai, China) according to the manufacturer’s instructions. For the determination of MDA content, the thiobarbituric acid (TBA) method was utilized, while the xanthine oxidase method was employed for the measurement of SOD activity. Intracellular ROS levels were measured using the DCFH-DA fluorescent probe. After H/R treatment, cells were incubated with 10 µM DCFH-DA for 20 min at 37℃ in the dark, then washed three times with PBS. Fluorescence intensity was detected using a fluorescence spectrophotometer at an excitation wavelength of 488 nm and an emission wavelength of 525 nm. ROS levels were expressed as a percentage of the control group (CK = 100%), and in the rescue experiments, as a percentage of the H/R group (H/R = 100%). Detection of apoptosis by flow cytometry Apoptosis was detected using an Annexin V-FITC/PI apoptosis detection kit (BD Biosciences, USA). After H/R treatment, H9c2 cells were collected, washed twice with cold PBS, and resuspended in 1× binding buffer. Then, 5 µL of Annexin V-FITC and 5 µL of PI were added, and the cells were incubated for 15 min at room temperature in the dark. Flow cytometric analysis was performed using a flow cytometer (BD FACS Canto II, BD Biosciences, USA). Cell viability Cell viability was assessed using the CCK-8 assay (Beyotime, Shanghai, China) [28]. Cells were seeded in 96-well plates and cultured for 24 h, then subjected to different treatments. Cell viability was measured at 0, 24, 48, and 72 h after treatment. At each time point, 10 µL of CCK-8 solution was added to each well and the plates were incubated at 37 °C for 1–4 h. The OD values were then measured at 450 nm using a microplate reader (Thermo Fisher Scientific, Waltham, MA, USA). Validation of the targeting relationship between miR-324-3p and STAT3 Identify the potential binding sites between miR-324-3p and the 3’-UTR of STAT3 mRNA via the TargetScan database. Construct STAT3 3’-UTR luciferase reporter vectors containing WT or MUT binding sites, co-transfect them with miR-324-3p mimics or NC into H9c2 cells. The dual-luciferase reporter assay was performed using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) according to the manufacturer’s instructions. The STAT3 gene rescue experiment was conducted by knocking down STAT3 expression with siRNA on the basis of miR-324-3p inhibitor transfection, followed by repeating the aforementioned cell function assays. By observing whether knocking down STAT3 reverses the protective effect of miR-324-3p inhibitors on H/R-injured cardiomyocytes, the critical role of STAT3 in the miR-324-3p regulatory pathway is elucidated. Western blot analysis H9c2 cells were lysed in RIPA buffer (Beyotime, Shanghai, China) supplemented with protease inhibitors. Protein concentrations were determined using a BCA protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA). Equal amounts of protein were separated by 10% SDS-PAGE and then transferred onto PVDF membranes (Millipore, Burlington, MA, USA). The membranes were first blocked with 5% non-fat milk for 1 h at room temperature, then incubated overnight at 4℃ with primary antibodies against STAT3 and β-actin. After washing with TBST, the membranes were incubated with an HRP-conjugated secondary antibody for 1 h at room temperature. Protein bands were visualized using an enhanced chemiluminescence kit (Thermo Fisher Scientific, Waltham, MA, USA), and quantification was carried out with ImageJ software (NIH, Bethesda, MD, USA) [29]. Statistical analysis Statistical analyses were conducted with the use of SPSS 23.0 and GraphPad Prism 7.0 software. Two-group comparisons were done via independent two-tailed t-test, while one-way ANOVA was used to evaluate differences across multiple groups, followed by Tukey’s post-hoc test for multiple comparisons. Data are presented as mean ± SD, with p-values less than 0.05 deemed statistically significant. For cell experiments, all experiments were independently repeated 5 times (n = 5 per group), with 3 technical replicates in each experiment. Both a priori and post-hoc power analyses were performed using G*Power 3.1 software based on the two independent samples t-test model (two-tailed). The a priori analysis, with a medium effect size of d = 0.5, α = 0.05, and power of 0.80, indicated that 64 participants per group were required. The actual sample sizes (control group n = 82, AMI group n = 77) exceeded this requirement. The post-hoc analysis achieved a power of 0.983 with an effect size of d = 0.65, α = 0.05, confirming that the current sample size was sufficient to detect the difference in miR-324-3p expression between the two groups. Results Clinical feature analysis According to Table 1, the control group and AMI patients showed no significant disparities in age, gender, BMI, smoking and drinking status, DBP, FBG, LDL-C, and TC (p > 0.05). However, the SBP and TG levels in AMI patients were significantly higher than those in the control group, while the HDL-C level was significantly lower than that in the control group (p < 0.05). Table 1Comparison of baseline data between control and experimental groupIndicatorsControls (n = 82)AMI patients (n = 77)p- ValueAge (years)53.93 ± 4.4152.9 ± 4.510.15Gender (M/F)39/4344/330.23BMI (kg/m2)24.04 ± 1.9324.04 ± 1.771.00Smoking (Y/N)37/4540/370.39Drinking (Y/N)42/4047/300.22SBP (mmHg)120.11 ± 12.95132.12 ± 11.22< 0.001DBP (mmHg)74.92 ± 8.4376.91 ± 7.390.12FBG (mmol/L)4.9 ± 0.594.95 ± 0.640.59LDL-C (mmol/L)2.78 ± 0.352.74 ± 0.370.48HDL-C (mmol/L)1.6 ± 0.291.17 ± 0.28< 0.001TC (mmol/L)4.4 ± 0.814.37 ± 0.70.81TG (mmol/L)1.28 ± 0.261.41 ± 0.310.01AMI, acute myocardial infarction; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride. M/F, male/female; Y/N, yes/no. The date was presented as mean ± SD, or percentage (/) Comparison of baseline data between control and experimental group AMI, acute myocardial infarction; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride. M/F, male/female; Y/N, yes/no. The date was presented as mean ± SD, or percentage (/) The expression level and diagnostic value of miR-324-3p According to the qRT-PCR results, the expression of serum miR-324-3p was up-regulated in the AMI group compared to the control group (Fig. 1A, p < 0.0001). The ROC curve revealed an AUC of 0.889 for miR-324-3p, with sensitivity and specificity of 0.831 and 0.793, respectively, corresponding to a cutoff value of 1.125 (Fig. 1B). Expression and clinical diagnostic value of miR-324-3p in AMI. (A) Expression levels of miR-324-3p in the serum of AMI patients (n = 77) and healthy controls (n = 82) (independent two-tailed t-test). (B) ROC curve analysis. ****p < 0.0001 The regulatory role of miR-324-3p on the function of cardiomyocytes injured by H/R As shown in Fig. 2A, contrasted with the normal control group (CK), the relative expression level of miR-324-3p in the H/R group cells was significantly increased. Meanwhile, all groups exhibited significant expression differences compared to their corresponding negative control (NC) groups, indicating that the experimental operations were effective and specific. The effect of miR-324-3p on the inflammatory response in the H/R injury cell model. (A) The effect of miR-324-3p transfection on the expression of miR-324-3p in cells after H/R treatment. The effect of miR-324-3p transfection on the production of (B) IL-6, (C) TNF-α, and (D) IL-1β in the H/R cell model. CK represents the normal control group; H/R represents the hypoxia-reoxygenation treatment group; IL-6 stands for interleukin-6; TNF-α denotes tumor necrosis factor-alpha; IL-1β refers to interleukin-1β. Data are presented as mean ± SD (n = 5 independent experiments per group). Comparisons among multiple groups were performed using one-way ANOVA followed by Tukey’s post-hoc test. ****p < 0.0001 H/R treatment significantly increased the levels of IL-6 (Fig. 2B), IL-1β (Fig. 2C), and TNF-α (Fig. 2D), suggesting that H/R injury can trigger cellular inflammatory responses and release a large amount of inflammatory factors. Overexpression of miR-324-3p significantly increases the levels of inflammatory factors within the cells, enhancing the release of IL-6, IL-1β, and TNF-α. However, after knocking down miR-324-3p, the levels of inflammatory factors within the cells were further reduced, effectively suppressing the inflammatory response triggered by H/R injury. The impact of miR-324-3p on myocardial cell viability and oxidative stress in H/R injury As can be seen from the cell viability assay results (Fig. 3A), H/R treatment significantly reduced cell viability, and H/R successfully induced cardiomyocyte injury. Overexpression of miR-324-3p further exacerbated the decline in cell viability, while knockdown of miR-324-3p partially restored cell viability. Therefore, miR-324-3p has a negative effect on maintaining the viability of cardiomyocytes under H/R conditions. H/R treatment resulted in a significant decrease in intracellular SOD activity (Fig. 3B), while MDA content significantly increased (Fig. 3C), indicating that H/R damage induced an oxidative stress response within the cells. Overexpression of miR-324-3p significantly increased MDA activity and decreased SOD content, indicating that miR-324-3p can effectively alleviate oxidative stress injury induced by H/R. Conversely, knockdown of miR-324-3p increased SOD activity and reduced MDA content, further confirming the protective role of miR-324-3p in regulating oxidative stress. In addition, the study found that H/R treatment significantly increased ROS levels, overexpression of miR-324-3p further elevated ROS levels, while inhibition of miR-324-3p reduced ROS levels (Fig. 3D). Apoptosis was further examined using Annexin V/PI double staining flow cytometry. The results showed that H/R treatment markedly increased the apoptosis rate, overexpression of miR-324-3p further enhanced the apoptosis rate, whereas inhibition of miR-324-3p significantly decreased the apoptosis rate (Fig. 3E-F). Effects of miR-324-3p on (A) cell viability, (B) SOD, (C) MDA, and (D) ROS levels. (E) Representative flow cytometry scatter plots of Annexin V/PI double staining. (F) Apoptosis rates. CK is the normal control group; H/R is the hypoxia-reoxygenation treatment group. The values shown are mean ± SD (n = 5 independent experiments per group). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post-hoc test. ****p < 0.0001 Validation of the targeting relationship between miR-324-3p and STAT3 Transfection efficiency validation showed that, compared with their respective negative controls, miR-324-3p expression was significantly increased in the miR-mimic group and significantly decreased in the miR-inhibitor group, with an inhibition efficiency of 70.7%, indicating successful transfection (Supplementary Fig. 1). The TargetScan human database predicted the downstream target genes of miR-324-3p (Fig. 4A). The dual-luciferase reporter gene assay demonstrated that overexpression of miR-324-3p significantly reduced the luciferase activity of WT-STAT3, while the knockdown of miR-324-3p increased the luciferase activity of WT-STAT3 (Fig. 4B). H/R treatment significantly reduced the expression of STAT3 (Fig. 4C). Western blot analysis showed that, compared with the CK group, H/R treatment significantly reduced STAT3 protein expression, while treatment with the miR-324-3p inhibitor significantly upregulated STAT3 protein levels (Fig. 4D). Furthermore, knockdown of STAT3 in the presence of the miR-324-3p inhibitor reversed the upregulation of STAT3 protein expression induced by the miR-324-3p inhibitor. Meanwhile, treatment with the miR-324-3p inhibitor significantly reduced miR-324-3p expression; however, further knockdown of STAT3 had no significant effect on miR-324-3p expression levels (Fig. 4E). Validation of the targeting relationship between miR-324-3p and STAT3. (A) Prediction of the miR-324-3p binding site on the 3’-UTR of STAT3. (B) Validation of the targeting relationship by dual-luciferase reporter assay. After H/R treatment, the effect of si-STAT3 transfection on intracellular levels of (C) STAT3 mRNA, (D) STAT3 protein (Western blot), and (E) miR-324-3p. The values shown are mean ± SD (n = 5 independent experiments per group). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post-hoc test. ****p < 0.0001 Compared with the si-NC group, STAT3 mRNA expression was significantly reduced in the si-STAT3 group, with a knockdown efficiency of 72%, indicating that si-STAT3 effectively knocked down STAT3 expression (Supplementary Fig. 1). CCK-8 assay results showed that the miR-324-3p inhibitor significantly increased the viability of H/R-injured cardiomyocytes, while knockdown of STAT3 reversed this protective effect (Fig. 5A). In the H9c2 cardiomyocyte H/R injury model, STAT3 knockdown significantly increased the release of IL-6 (Fig. 5B), TNF-α (Fig. 5C), and IL-1β (Fig. 5D) compared to the NC group. Furthermore, compared to the NC group, knockdown of STAT3 significantly increased the intracellular MDA content (Fig. 5E) and markedly reduced SOD activity (Fig. 5F). In addition, treatment with the miR-324-3p inhibitor significantly reduced ROS levels, and knockdown of STAT3 partially reversed this effect (Fig. 5G). Representative scatter plots and quantification of apoptosis rates (Fig. 5H-I) showed that treatment with the miR-324-3p inhibitor decreased the apoptosis rate compared with the H/R group. However, knockdown of STAT3 significantly increased the apoptosis rate compared with the negative control group, further confirming that STAT3 is a key target through which miR-324-3p regulates oxidative stress and apoptosis. The impact of STAT3 on cellular damage, inflammatory response, and oxidative stress under H/R conditions. (A) The cell viability of myocardial cells in each group under H/R conditions. The levels of (B) IL-6, (C) TNF-α, (D) IL-1β, (E) MDA content, (F) SOD activity, and (G) ROS levels in the cell culture supernatant of each group. (H) Representative flow cytometry scatter plots of Annexin V/PI double staining. (I) Apoptosis rates. The values shown are mean ± SD (n = 5 independent experiments per group). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post-hoc test. ****p < 0.0001 Discussion AMI is an acute myocardial necrosis caused by local myocardial ischemia and hypoxia, characterized by high morbidity and mortality rates, posing a serious threat to patients’ lives [30]. According to epidemiological surveys, AMI affects more than 7 million people globally, with an annual mortality rate of approximately 10% [31]. Hs-TnT has high sensitivity, which can shorten the “troponin blind period” and rapidly identify AMI patients. NT-proBNP is used for the diagnosis of heart failure, but their specificity is limited and may be interfered with by other myocardial injuries [32]. Therefore, it is imperative to explore more sensitive and specific biomarkers to compensate for the shortcomings of current markers and facilitate the early diagnosis and treatment of AMI. Numerous studies have demonstrated that miRNAs play a crucial regulatory role in the normal physiological functions and pathological changes of the heart through their interactions with target mRNAs [3]. H/R injury is an inevitable part of the treatment process for AMI. In this context, studies have found that miR-324-3p may influence the onset and progression of myocardial H/R injury by regulating processes such as inflammation, oxidative stress, and cell apoptosis [10–12, 33]. However, the functional role of miR-324-3p appears to be highly context-dependent. For example, it is highly expressed in renal fibrosis and promotes collagen deposition [34], but its expression is downregulated in diabetic nephropathy, and restoring miR-324-3p levels alleviates fibrosis [35]. These pleiotropic effects suggest that miR-324-3p may exert different biological functions depending on the specific cellular environment and disease state. In this study, miR-324-3p levels were markedly elevated in the AMI group relative to the control group. This elevation is likely attributable to AMI, a finding consistent with Wang et al. [36]. ROC curve analysis further validated the diagnostic efficacy of miR-324-3p for AMI (AUC = 0.889), suggesting its potential as a candidate biomarker for the clinical diagnosis of AMI. The H9c2 cells selected for this experiment are a type of rat cardiac progenitor cells that can mimic the characteristics of cardiomyocytes. By constructing an H/R injury model, it is possible to effectively replicate the pathological processes of myocardial ischemia, hypoxia, and reperfusion following the occurrence of AMI in vivo. IL-1β, IL-6, and TNF-α are crucial inflammatory mediators involved in the inflammatory response [37, 38]. Following the occurrence of AMI, the necrosis of myocardial cells activates a local immune response, attracting a large number of inflammatory cells to infiltrate and release inflammatory factors [39]. These inflammatory factors will further exacerbate the damage and death of myocardial cells, leading to myocardial remodeling and a decline in cardiac function [40]. During myocardial ischemia-reperfusion, a large amount of ROS triggers oxidative stress, which reduces the activity of intracellular SOD and increases the content of MDA [41]. This study confirmed that miR-324-3p can exacerbate H/R-induced cardiomyocyte injury, reduce cell viability, and increase the secretion of inflammatory factors and oxidative stress markers. This suggests that miR-324-3p may influence the progression of AMI by regulating inflammation and oxidative stress. The STAT3 signaling pathway plays a crucial role in the regulation of apoptosis induced by various factors such as myocardial infarction and tumors [42]. Through TargetScan prediction, it was found that miR-324-3p has a potential binding site with STAT3. STAT3, as a signal transducer and activator of transcription, plays a central role in the inflammatory response and apoptosis process during myocardial infarction. However, the interaction between miR-324-3p and STAT3 may not be exclusive. A growing body of evidence indicates that miR-324-3p can regulate multiple signaling pathways depending on the cellular context. For instance, in viral myocarditis, it targets TRIM27 to suppress the MAPK/ERK pathway, thereby reducing myocardial inflammation and viral replication [43]. In inflammatory bowel disease, it is highly expressed in inflamed mucosal tissues and helps regulate both the T cell receptor signaling pathway and the NOD-like receptor signaling pathway [44]. In atherosclerosis, it inhibits macrophage apoptosis through NOS1 and participates in vascular calcification via the IGF1R/PIK3CA/MAP2K1 axis [45]. In addition, abnormal activation of STAT3 can reduce myocardial injury [46]. Activated STAT3 can influence the expression of multiple genes [47]. These findings suggest that miR-324-3p plays a key role in the crosstalk between multiple signaling pathways. Compared with these studies, our work further confirms a new mechanism by which miR-324-3p regulates inflammation and oxidative stress in AMI through targeting STAT3, thus enriching the functional network of miR-324-3p in myocardial injury. This study has certain limitations. First, the relatively small clinical sample size may affect the comprehensive evaluation of the diagnostic efficacy of miR-324-3p. Therefore, multi-center, large-scale prospective studies are needed to externally validate our findings. Moreover, STAT3 occupies a pivotal position in cellular signal transduction, and the signaling pathways it participates in regulating are intricate and complex [48]. In the development of AMI, STAT3 is involved in numerous signaling pathways, such as JAK/STAT [49]. Current research has confirmed that miR-324-3p affects inflammation and oxidative stress related to AMI by targeting STAT3, but the specific mechanisms of action of the numerous signaling pathways involved in STAT3 in this process have not yet been fully explained. Thus, future research should clarify the specific contributions of each pathway in the miR-324-3p/STAT3 axis in regulating AMI, thereby providing a solid theoretical foundation for developing more precise and effective AMI treatment strategies. Conclusion In summary, the level of miR-324-3p in the serum of AMI patients is significantly elevated, providing important value for the clinical diagnosis of AMI. miR-324-3p exacerbates cardiomyocyte injury and regulates this damage by targeting STAT3, affecting inflammatory responses and oxidative stress processes. Supplementary Information Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Acknowledgements Not applicable. Author contributions HXL was responsible for project development, data management, data analysis, manuscript writing and manuscript editing. WJZ, WZW, and RST were responsible for data management, data acquisition and data analysis. All authors have read and approved the manuscript. Funding This study was funded by “To investigate the relationship between MBF parameters, hs-TnT and LVEF in STEMI patients” Medical Science Research Project of Hebei (20231740). Data availability The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was performed in line with the principles of the Declaration of Helsinki. This work has been approved by the Ethics Committee of Tangshan Third Hospital. Informed consent was obtained from all individual participants included in the study. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.